“Gilead Sciences’ Trodelvy in combination with Merck’s blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to results of a large trial presented on Saturday.

The data is likely to change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert said.”

From Reuters.